Clinical efifcacy observation of Tiotropium Bromide with different doses on chronic obstructive pulmonary disease
- VernacularTitle:不同剂量噻托溴铵吸入治疗慢性阻塞性肺疾病的临床疗效观察
- Author:
Jiahua CHEN
;
Shuliang GUO
- Publication Type:Journal Article
- Keywords:
chronic obstructive pulmonary disease;
tiotropium bromide;
observational study
- From:
Chinese Journal of Biochemical Pharmaceutics
2014;(2):86-89
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical efifcacy of Tiotropium Bromide inhaler on patients with stable chronic obstructive pulmonary disease(COPD). Methods 134 cases with stable COPD were equally randomized into three groups. The conventional treatment group(n=46) were 40 male and 6 femal, aged (63.20±9.3)years old and treated with sustained-release theophylline 0.1 g orally. Observation group with 18μg Tiotropium Bromide(n=45) were 40 male and 5 femal, aged (63.4±85)years old, and given inhaled Tiotropium Bromide 18μg. Observation group with 32μg Tiotropium Bromide(n=43) were 39 male and 4 femal, aged (63.2±9.0)years old, and given inhaled Tiotropium Bromide 32 μg. All patients received same routine therapy, and lasted for 4 weeks. improvement Pre-and post-treatment Lung function and quality of life were compared among those groups. Results In observation group, the results of St George respiratory questionnaire decreased signiifcantly after treatment, which was signiifcantly lower than those of the routine-treatment group (P<0.05). FEV 1/FVC, FEV 1/Pred, FEV 1 were signiifcantly higher than those before treatment (P<0.05). However, the control group showed no signiifcant difference. Conclusion Inhaled Tiotropium Bromide can improve lung function and life quality of paitents with stable COPD, the dose with 32μg per day, which was signiifcantly lower than 18μg per day.
